It was registered an increase on Avrobio Inc (NASDAQ:AVRO)’s short interest with 16.63%. FINRA issued in March AVRO’s total 694,300 short interest. The up change of 16.63% from 595,300 shares was reported. With Average volume 269,300, AVRO’s former position will take 3 days to restore. 6.76% is Avrobio Inc float short.

AVRO is reaching $13.75 during the last trading session, after decreased 8.33%.Currently AVROBIO, Inc. is after 0.00% change in last March 6, 2018. AVRO has also 95,444 shares volume. AVRO underperformed by 4.37% the S&P 500.

AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral gene therapies to treat rare diseases following a single dose.The firm is worth $326.86 million. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease.Last it reported negative earnings. The Company’s lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of fabry disease.

For more AVROBIO, Inc. (NASDAQ:AVRO) news posted recently go to: Seekingalpha.com, Globenewswire.com, Nasdaq.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “AVROBIO updates on gene therapy for Fabry – Seeking Alpha” posted on February 06, 2019, “AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019 – GlobeNewswire” on February 01, 2019, “AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors – Nasdaq” with a publish date: January 07, 2019, “Two biotech IPOs were just acquired for $1+ billion each – Nasdaq” and the last “Key events next week – healthcare – Seeking Alpha” with publication date: February 01, 2019.